Pancreatic Ductal Adenocarcinoma (PDAC) is the 3rd leading cause of cancer death in the US. We performed loss of function genomic screening on a cohort of four patient derived PDAC cell populations and our data shows a cell surface receptor CD109 to be a common vulnerability, the biologic role of which in PDAC is yet unstudied and largely unknown. We hypothesized that CD109 expression provides PDAC cells with a survival advantage, and promotes cancer progression through activation of downstream signaling. We believe therefore that targeting CD109 could improve PDAC patients’ survival. Here we report that CD109 plays a role in cell proliferation, viability, and clonogenicity in vitro. We also find that it promotes tumor formation and progression in nude mice, therefore decreasing their survival. We revealed an association between CD109 expression and YAP/TAZ signaling through RPPA and RNA Sequencing data. This data establishes CD109 as a cell surface protein exclusively expressed in PDAC rather than healthy pancreatic tissue, demonstrating pro-oncogenic behavior and tumor initiation potential in vitro and in vivo. This helps us understand more about PDAC and provides insights into a relatively unknown protein with a therapeutic potential.
","abstract_html":"<p>Pancreatic Ductal Adenocarcinoma (PDAC) is the 3rd leading cause of cancer death in the US. We performed loss of function genomic screening on a cohort of four patient derived PDAC cell populations and our data shows a cell surface receptor CD109 to be a common vulnerability, the biologic role of which in PDAC is yet unstudied and largely unknown. We hypothesized that CD109 expression provides PDAC cells with a survival advantage, and promotes cancer progression through activation of downstream signaling. We believe therefore that targeting CD109 could improve PDAC patients’ survival. Here we report that CD109 plays a role in cell proliferation, viability, and clonogenicity in vitro. We also find that it promotes tumor formation and progression in nude mice, therefore decreasing their survival. We revealed an association between CD109 expression and YAP/TAZ signaling through RPPA and RNA Sequencing data. This data establishes CD109 as a cell surface protein exclusively expressed in PDAC rather than healthy pancreatic tissue, demonstrating pro-oncogenic behavior and tumor initiation potential <em>in vitro</em> and <em>in vivo</em>. This helps us understand more about PDAC and provides insights into a relatively unknown protein with a therapeutic potential.</p>","abstract_has_math":false,"creators":["Shaheen, MennatAllah","http://www.orcid.org/0000-0001-5041-4218
"],"institution":null,"degree_name":"Masters of Science (MS)","degree_level":"Thesis (MS)","degree_discipline":null,"degree_department":null,"school":null,"contributors":["Giulio F. Draetta","Swathi Arur","Richard Behringer"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2019,"date_issued":"2019-08-01T07:00:00Z","date_published":"2019-08-01T07:00:00Z","updated_at":"2026-07-24T05:50:16Z","subjects":["CD109","PDAC","cancer","pancreas","functional genomics","Biology","Genetics","Genomics","Medicine and Health Sciences"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.library.tmc.edu/utgsbs_dissertations/971","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Giulio F. Draetta","Swathi Arur","Richard Behringer"]},{"key":"dc:creator","label":"Author","values":["Shaheen, MennatAllah","http://www.orcid.org/0000-0001-5041-4218
"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2019-08-14T07:00:00Z"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis (MS)"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Masters of Science (MS)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["CD109","PDAC","cancer","pancreas","functional genomics","Biology","Genetics","Genomics","Medicine and Health Sciences"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.library.tmc.edu/utgsbs_dissertations/971"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Pancreatic Ductal Adenocarcinoma (PDAC) is the 3rd leading cause of cancer death in the US. We performed loss of function genomic screening on a cohort of four patient derived PDAC cell populations and our data shows a cell surface receptor CD109 to be a common vulnerability, the biologic role of which in PDAC is yet unstudied and largely unknown. We hypothesized that CD109 expression provides PDAC cells with a survival advantage, and promotes cancer progression through activation of downstream signaling. We believe therefore that targeting CD109 could improve PDAC patients’ survival. Here we report that CD109 plays a role in cell proliferation, viability, and clonogenicity in vitro. We also find that it promotes tumor formation and progression in nude mice, therefore decreasing their survival. We revealed an association between CD109 expression and YAP/TAZ signaling through RPPA and RNA Sequencing data. This data establishes CD109 as a cell surface protein exclusively expressed in PDAC rather than healthy pancreatic tissue, demonstrating pro-oncogenic behavior and tumor initiation potential in vitro and in vivo. This helps us understand more about PDAC and provides insights into a relatively unknown protein with a therapeutic potential.
"]},{"key":"dc:title","label":"Title","values":["Investigating The Role of Cd109 In Pancreatic Ductal Adenocarcinoma"]}]}],"canonical_facts":{"dc:contributor":["Giulio F. Draetta","Swathi Arur","Richard Behringer"],"dc:creator":["Shaheen, MennatAllah","http://www.orcid.org/0000-0001-5041-4218
"],"dc:date.available":["2019-08-14T07:00:00Z"],"dc:description.abstract":["Pancreatic Ductal Adenocarcinoma (PDAC) is the 3rd leading cause of cancer death in the US. We performed loss of function genomic screening on a cohort of four patient derived PDAC cell populations and our data shows a cell surface receptor CD109 to be a common vulnerability, the biologic role of which in PDAC is yet unstudied and largely unknown. We hypothesized that CD109 expression provides PDAC cells with a survival advantage, and promotes cancer progression through activation of downstream signaling. We believe therefore that targeting CD109 could improve PDAC patients’ survival. Here we report that CD109 plays a role in cell proliferation, viability, and clonogenicity in vitro. We also find that it promotes tumor formation and progression in nude mice, therefore decreasing their survival. We revealed an association between CD109 expression and YAP/TAZ signaling through RPPA and RNA Sequencing data. This data establishes CD109 as a cell surface protein exclusively expressed in PDAC rather than healthy pancreatic tissue, demonstrating pro-oncogenic behavior and tumor initiation potential in vitro and in vivo. This helps us understand more about PDAC and provides insights into a relatively unknown protein with a therapeutic potential.
"],"dc:identifier":["https://digitalcommons.library.tmc.edu/utgsbs_dissertations/971"],"dc:subject":["CD109","PDAC","cancer","pancreas","functional genomics","Biology","Genetics","Genomics","Medicine and Health Sciences"],"dc:title":["Investigating The Role of Cd109 In Pancreatic Ductal Adenocarcinoma"],"thesis:degree_level":["Thesis (MS)"],"thesis:degree_name":["Masters of Science (MS)"]},"updated_at":"2026-07-24T05:50:16Z"}